2014
DOI: 10.2174/1567205011666140505111354
|View full text |Cite
|
Sign up to set email alerts
|

Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse

Abstract: Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with 18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β-amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG uptake, to search for an early biomarker distinguishing 5XF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
82
1

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 65 publications
(86 citation statements)
references
References 37 publications
(51 reference statements)
3
82
1
Order By: Relevance
“…Many of these mouse models develop Aβ‐plaque pathology and cognitive dysfunction, but much less is known about how well they recapitulate the sensori‐motor deficits seen in AD. The transgenic 5xFAD mouse develops many pathological changes observed in AD including cognitive impairment a rapid development of Aβ‐plaques, astro‐ and micro‐gliosis, cortical cell loss and reduced cerebral glucose uptake . The 5xFAD mouse also shows motor dysfunction after 9 months of age .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Many of these mouse models develop Aβ‐plaque pathology and cognitive dysfunction, but much less is known about how well they recapitulate the sensori‐motor deficits seen in AD. The transgenic 5xFAD mouse develops many pathological changes observed in AD including cognitive impairment a rapid development of Aβ‐plaques, astro‐ and micro‐gliosis, cortical cell loss and reduced cerebral glucose uptake . The 5xFAD mouse also shows motor dysfunction after 9 months of age .…”
Section: Introductionmentioning
confidence: 99%
“…The transgenic 5xFAD mouse develops many pathological changes observed in AD including cognitive impairment 19,20 a rapid development of Aβ-plaques, 20 astro-and micro-gliosis, 21 cortical cell loss 22 and reduced cerebral glucose uptake. 23 The 5xFAD mouse also shows motor dysfunction after 9 months of age. 22,24 Therefore, the 5xFAD mouse may be a particularly useful animal model to examine the development of motor dysfunction in AD, and these motor deficits may be useful in the assessment of novel therapeutics.…”
Section: Introductionmentioning
confidence: 99%
“…Many of these mouse models develop Aβ‐plaque pathology and cognitive dysfunction, but much less is known about their development of age‐related sensorimotor deficits as occurs in AD . The majority of AD mouse models take over 6‐months to develop phenotypic symptoms, but the transgenic 5xFAD mouse model exhibits amyloid plaques before 2 months of age and recapitulates many pathological changes observed in AD, including cognitive impairment, neuronal cell loss and reduced cerebral glucose uptake …”
Section: Introductionmentioning
confidence: 99%
“…9 The majority of AD mouse models take over 6-months to develop phenotypic symptoms, but the transgenic 5xFAD mouse model exhibits amyloid plaques before 2 months of age 10 and recapitulates many pathological changes observed in AD, including cognitive impairment, 10,11 neuronal cell loss 12 and reduced cerebral glucose uptake. 13 Behaviourally, the 5xFAD mice have memory impairments, showed by a lack of recognition for novel objects at 6 to 7 months of age 14 and spatial memory deficits. 15,16 They also have motor impairments after 9 months of age, [17][18][19] age-related deafness 20 and social impairments 11 from 12 months of age.…”
Section: Introductionmentioning
confidence: 99%
“…However these discrepancies may also be accounted for by methodological factors [ 30 ] in addition to strain differences. More recently in vivo hypometabolism in amyloidosis models has been described [ 31 33 ].…”
Section: Introductionmentioning
confidence: 99%